Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 356

Sort by

Sort Order Select

Journal Articles

Oral Arginine Therapy As a Novel Adjuvant in the Management of Acute Pain in Children with Sickle Cell Anemia in Nigeria: A Randomized Placebo-Controlled Trial

Richard Onalo, FCPaed, Peter Cooper, FCPaed, Antoinette Cilliers, FCPaed, Uche Nnebe-Agumadu, FCPaed, Oluseyi Oniyangi, FCPaed, Damilare Oladimeji, MSc Statistics, Claudia R. Morris, MD

Blood (2019) 134 (Supplement_1): 613.

https://doi.org/10.1182/blood-2019-122510

Published: 2019

Journal Articles

Acute Myeloid Leukemia (AML) in a 3D Bone Marrow Niche Showed High Performance for in Vitro and In Vivo Drug Screenings

Giulia Borella, Ambra Da Ros, Elena Porcù, PhD, Claudia Tregnago, PhD, Maddalena Benetton, Valeria Bisio, PhD, Elisabetta Campodoni, Silvia Panseri, PhD, Monica Sandri, PhD, Monica Montesi, PhD, Stefano Cairo, PhD, Franco Locatelli, MD PhD, Martina Pigazzi, PhD

Blood (2019) 134 (Supplement_1): 544.

https://doi.org/10.1182/blood-2019-128382

Published: 2019

Journal Articles

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Moritz Binder, MDMPH, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD, Jessica L. Haug, Angela Dispenzieri, MD, Kimberly J. Henderson, Teresa K. Kimlinger, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 1772.

https://doi.org/10.1182/blood-2019-123407

Published: 2019

Journal Articles

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Nizar Bahlis, MD, Jeffrey A. Zonder, Susan Wroblewski, PhD, Ming Qi, MD PhD, Thomas Renaud, Carolyn Jackson, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 1831.

https://doi.org/10.1182/blood-2019-123486

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Blood (2019) 134 (Supplement_1): 1865.

https://doi.org/10.1182/blood-2019-122765

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Blood (2019) 134 (Supplement_1): 1906.

https://doi.org/10.1182/blood-2019-122501

Published: 2019

Journal Articles

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy S. Pardee, MD PhD, Kris C Wood, PhD, Kevin H Lin, BS, Justine Rutter, PhD, Mariaelena Pierobon, MD, Emanuel Petricoin, PhD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 1388.

https://doi.org/10.1182/blood-2019-129413

Published: 2019

Journal Articles

Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets

Cassandra M Kerr, MS, Vera Adema, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Christina A. Snider, BA, Yasunobu Nagata, MD PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Thomas Laframboise, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1703.

https://doi.org/10.1182/blood-2019-126866

Published: 2019

Journal Articles

Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

Nina D. Shah, MD, Yana Lutska, PharmD, Huiling Pei, PhD, Ming Qi, MD PhD, Maria Krevvata, PhD, Colleen Kane, PhD VMD, Jon Ukropec, PhD, Thomas S. Lin, MD PhD, Shalaka Hampras, MBBS, PhD MPH

Blood (2019) 134 (Supplement_1): 1829.

https://doi.org/10.1182/blood-2019-122471

Published: 2019

Journal Articles

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Bachisio Ziccheddu, PhD, Giulia Biancon, Chiara De Philippis, MD, Filippo Bagnoli, MD, Francesco Maura, MD, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi, Carolina Terragna, Marina Martello, Tina Bagratuni, PhD, Eftathios Kastritis, Meletios A. Dimopoulos, MD, Michele Cavo, Cristiana Carniti, PhD, Vittorio Montefusco, Paolo Corradini, Niccolo Bolli, MD PhD

Blood (2019) 134 (Supplement_1): 3056.

https://doi.org/10.1182/blood-2019-122197

Published: 2019

Journal Articles

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Blood (2019) 134 (Supplement_1): 3091.

https://doi.org/10.1182/blood-2019-130247

Published: 2019

Journal Articles

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

Alexandre Sostelly, M.Eng., PhD, Antoine Soubret, Christoph Bucher, MD, Simon Buatois, Jean-Eric Charoin, Gregor Jordan, Barbara Klughammer, PhD, Andreas Dieckmann, Taku Fukuzawa, PhD, Keisuke Gotanda, Kenji Shinomiya, Sung-Soo Yoon, MD PhD, Jens P. Panse, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD, Zsolt Nagy, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 1227.

https://doi.org/10.1182/blood-2019-126911

Published: 2019

Journal Articles

Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress

Claudia R. Morris, MD, Janet Figueroa, MPH, Amanda Watt, Kirshma Khemani, MD, Polly Kumari, MBBS, Morgan Barnett, MPH, Nitya Bakshi, MBBS, MS, Peter A. Lane, MD, Carlton Dampier, MD

Blood (2019) 134 (Supplement_1): 995.

https://doi.org/10.1182/blood-2019-122983

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Jihad Aljabban, MMSc, BA, David Chen, BS, Francesca Cottini, MD, Saad Syed, BS, Nabeal Aljabban, BS, Sharjeel Syed, BS, Tiffany Hughes, PhD, David Feldman, BS, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2019) 134 (Supplement_1): 4395.

https://doi.org/10.1182/blood-2019-129699

Published: 2019

Journal Articles

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Catherine Diefenbach, MD, Linda Lam, PhD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Peter Martin, FRCPC, MD MS, Jia Ruan, MD PhD, John P. Leonard, MD, Pratip Chattopadhyay, PhD

Blood (2019) 134 (Supplement_1): 3980.

https://doi.org/10.1182/blood-2019-128366

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

A High-Throughput Drug Screen Reveals a Novel Compound Class That Significantly Depletes IRF4 Expression in Multiple Myeloma

Elizabeth D. Lightbody, PhD, Mairead Reidy, PhD, Michael P. Agius, PhD, Salma El-Behaedi, BSc, Romanos Sklavenitis-Pistofidis, MD, Salomon Manier, MD PhD, Irene M. Ghobrial, MD

Blood (2019) 134 (Supplement_1): 5545.

https://doi.org/10.1182/blood-2019-130910

Published: 2019

Journal Articles

Identification of a Specific Immunophenotype Associated with a Consistent Pattern of Genetic Mutations Including Srsf 2 and Gene Expression Profile in MDS

Wolfgang Kern, MD, Wencke Walter, PhD, Manja Meggendorfer, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 4255.

https://doi.org/10.1182/blood-2019-130095

Published: 2019

Journal Articles

Identification of Tractable Drug-like eIF4Al Inhibitors with Potent Anti-Tumor Activity

Tyler A. Cunningham, BS, Derek Essegian, BS, MS, Stephan Schürer, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 5760.

https://doi.org/10.1182/blood-2019-130494

Published: 2019

NARROW

Oral Arginine Therapy As a Novel Adjuvant in the Management of Acute Pain in Children with Sickle Cell Anemia in Nigeria: A Randomized Placebo-Controlled Trial

Acute Myeloid Leukemia (AML) in a 3D Bone Marrow Niche Showed High Performance for in Vitro and In Vivo Drug Screenings

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets

Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma

Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

A High-Throughput Drug Screen Reveals a Novel Compound Class That Significantly Depletes IRF4 Expression in Multiple Myeloma

Identification of a Specific Immunophenotype Associated with a Consistent Pattern of Genetic Mutations Including Srsf 2 and Gene Expression Profile in MDS

Identification of Tractable Drug-like eIF4Al Inhibitors with Potent Anti-Tumor Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only